Teresa S. Kim

City Of Hope National Medical Center — United States

Medicine · Health Sciences

26h-index3.3kcitations145works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(43), Gastrointestinal Tumor Research and Treatment(40), CAR-T cell therapy research(33), Sarcoma Diagnosis and Treatment(23), Hedgehog Signaling Pathway Studies(19)

Publications145 total

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease
Blood·2025
Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease
Blood·2024· 2 cited
CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study
Blood·2024· 15 cited
Retraction: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance
Clinical Cancer Research·2024Open Access
PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease.
Journal of Clinical Oncology·2024· 4 cited
Abstract 5532: Differences in immune contexture across metastatic sites and tissue compartments in ovarian cancer
Cancer Research·2024
Abstract 2710: Combination CXCR4 and PD-1 blockade increases T cell infiltration and effector function in fibrolamellar carcinoma (FLC)
Cancer Research·2024
Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade
Research Square (Research Square)·2023· 1 citedOpen Access
Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study
Blood·2023· 3 cited
Histopathologic response to neoadjuvant chemotherapy: Prognostic value independent of BRCA status or bevacizumab use (2275)
Gynecologic Oncology·2023Open Access
Production of an interleukin-10 blocking antibody by genetically engineered macrophages increases cancer cell death in human gastrointestinal tumor slice cultures
Cancer Gene Therapy·2023· 5 cited
Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies
Journal for ImmunoTherapy of Cancer·2023· 15 citedOpen Access
A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.
Journal of Clinical Oncology·2023· 4 cited
Table S2 from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
2023Open Access
Supplementary table 1 from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
2023Open Access
Data from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
2023Open Access
Figure S1 from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
2023Open Access
Figure S1 from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
2023Open Access
Figure S4 from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
2023Open Access
Supplementary table 1 from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Ronald P. DeMatteo(11), Shan Zeng(10), Adrian M. Seifert(9), Noah A. Cohen(8), Megan H. Crawley(8), Michael J. Cavnar(7), Jonathan B. Greer(7), Venu G. Pillarisetty(6), Seth M. Pollack(6), Ferdinand Rossi(6), Eric C. Sorenson(6), Benjamin L. Green(6), Kimberly S. Smythe(5), Robert H. Pierce(5), Peter Besmer(5), Cristina R. Antonescu(5), Stephen J. Forman(5), Yongwoo David Seo(4), Xiuyun Jiang(4), Kevin M. Sullivan(4)